Jagsonpal Pharmaceuticals reports a 28.8% revenue growth to 2,687 million and a 59% increase in operating EBITDA to 579 million for FY25, with a proposed 125% dividend per share. The announcement is dated May 6, 2025, covering the fiscal year ending March 31, 2025.